




NewLink Genetics Corporation
Investor Relations Department
2503 South Loop Drive
Ames, IA 50010
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

Company Profile

Founded in 1999, NewLink Genetics is an immuno-oncology company focused on discovering and developing novel products for the treatment of cancer. The drug discovery and development teams at NewLink Genetics are relentlessly pursuing a wide range of immuno-oncology portfolio candidates with the potential to change the oncology landscape. NewLink Genetics' portfolio includes two small-molecule product candidates currently in clinical development. These product candidates inhibit the IDO pathway, a key immuno-oncology target, and focus on breaking the immune system's tolerance to cancer.

Press Releases [\[View all \]](#)

Jul 28, 2017

[NewLink Genetics Reports Second Quarter 2017 Financial Results and Updates Indoximod Program](#)

Jul 27, 2017

[NewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802](#)

Jul 10, 2017

[NewLink Genetics Receives Notice of Allowance from USPTO Covering Indoximod Salts and Prodrugs](#)

Jul 7, 2017

[NewLink Genetics to Host Its Second Quarter 2017 Financial Results Conference Call on July 28, 2017](#)

Jun 23, 2017

[Positive Phase 1b Data for NewLink Genetics' IDO Pathway Inhibitor, Indoximod, in Combination with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia \(AML\) Presented at the European Hematologic Association \(EHA\) Congress in Madrid, Spain](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Mar 6, 2017

[Annual Report \(10-K\)](#)

Mar 31, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 3, 2017

[Quarterly Report \(10-Q\)](#)

May 5, 2017

[Quarterly Report \(10-Q\)](#)

Nov 8, 2016

[Quarterly Report \(10-Q\)](#)